As of Thursday close, Corbus Pharmaceuticals Holdings Inc.’s (NASDAQ:CRBP) stock was down -$0.03, moving down -11.36 percent to $0.21. The average number of shares traded per day over the past five days has been 1,087,400 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.1051 fall in that time frame. In the last twenty days, the average volume was 614,765, while in the previous 50 days, it was 1,012,118.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, CRBP stock retreated -48.50%. Shares of the company fell to $0.2080 on 05/12/22, the lowest level in the past month. A 52-week high of $2.29 was reached on 01/03/22 after having rallying from a 52-week low of $0.23. Since the beginning of this year, CRBP’s stock price has dropped by -65.89% or -$0.4057, and marked a new high 1 time. However, the stock has declined by -90.83% since its 52-week high.
Corbus Pharmaceuticals Holdings Inc. (CRBP) last reported insider trading activity 64 days ago on Mar 10. Moran Sean F., the Chief Financial Officer of the company, purchased of 15,000 shares for $0.37 on Mar 10. It resulted in a $5,550 investment by the insider. Millian Craig Stuart added 10,000 shares at an average price of $0.37 on Mar 10. The insider now owns 22,000 shares following the transaction. On Mar 09, Chief Executive Officer Cohen Yuval bought 8,600 shares at $0.37 apiece. The transaction was valued at $3,182.
The stock’s beta is 2.02. Besides these, the trailing price-to-sales (P/S) ratio of 31.46, the price-to-book (PB) ratio of 0.38.
In the three months ended September 29, Corbus Pharmaceuticals Holdings Inc.’s quick ratio stood at 5.90, while its current ratio was 5.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.23, and the total debt-to-equity ratio was 0.28. Based on annual data, CRBP earned $56.87 million in gross profit and brought in $0.88 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -63.20%. Return on equity (ROE) for the past 12 months was -57.90%.
In Corbus Pharmaceuticals Holdings Inc.’s quarter-end financial report for September 29, it reported total debt of $13.73 million against cash and short-term investments of $29.09 million. While analysts expected Corbus Pharmaceuticals Holdings Inc. to report -$0.11 quarterly earnings, the actual figure was -$0.02 per share, beating the consensus estimate by 81.80%. During the quarter, the company generated -$7.52 million in EBITDA. The liabilities of Corbus Pharmaceuticals Holdings Inc. were 34.52 million at the end of its most recent quarter ended September 29, and its total debt was $25.9 million. The value of shareholders’ equity is $125.26 million.
This quick technical analysis looks at Corbus Pharmaceuticals Holdings Inc.’s (CRBP) price momentum. With a historical volatility rate of 47.40%, the RSI 9-day stood at 10.24% on 12 May.
With respect to its five-day moving average, the current Corbus Pharmaceuticals Holdings Inc. price is down by -33.35% percent or -$0.1051. At present, CRBP shares trade -47.50% below its 20-day simple moving average and -69.65% percent below its 100-day simple moving average. However, the stock is currently trading approximately -41.19% below its SMA50 and -85.81% below its SMA200.
Stochastic coefficient K was 3.68% and Stochastic coefficient D was 3.86%, while ATR was 0.0352. Given the Stochastic reading of 1.24% for the 14-day period, the RSI (14) reading has been calculated as 20.16%. As of today, the MACD Oscillator reading stands at -0.0516, while the 14-day reading stands at -0.0710.
Corbus Pharmaceuticals Holdings Inc. downgraded its rating on Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) to a Neutral in a note to investors on September 08, 2020. The analysts firm previously had a Buy rating on the stock.Corbus Pharmaceuticals Holdings Inc. (CRBP) has been rated Overweight by analysts. According to 0 brokerage firms, CRBP is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Corbus Pharmaceuticals Holdings Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $3.00, the current consensus forecast for the stock is $3.00 – $3.00. Based on these forecasts, analysts predict Corbus Pharmaceuticals Holdings Inc. (CRBP) will achieve an average price target of $3.00.